The research work of our team relies on the strong collaboration between scientists, biologists and clinicians, and the existence of a tumor biobank storing unique collections of lymphoma tissues, continuously supplied through an optimized circuit to collect tumor and a clinical network of over 3 million inhabitants.
Fundamental research focusses on two main axes:
- the study of the differentiation of normal B lymphocytes and their deregulation through lymphomagenesis,
- the study of the lymph node microenvironment, most specifically the lymphoid stromal cells, the myeloid cells and the CD4 follicular helper lymphocytes, and their deregulation through lymphomagenesis.
Building on the results of the fundamental research activities, translational research projects are developed, in partnership with industries and French and international academic partners, that focus on the discovery of blood biomarkers for lymphomas having prognostic or predictive value of the response to novel therapeutics and, the use of the immunoregulatory properties of mesenchymal stromal cells for dysimmunitary diseases and regenerative medicine. These translational developments take place within the SITI laboratory.